News

Video

Dr Facon on the Efficacy of Isa-VRd in Newly Diagnosed Multiple Myeloma

Conference|ASCO Annual Meeting

Thierry Facon, MD, discusses findings from the phase 3 IMROZ trial investigating Isa-VRd in patients with newly diagnosed multiple myeloma.

Thierry Facon, MD, professor, hematology, Department of Hematology, Lille University Hospital, discusses findings from the phase 3 IMROZ trial (NCT03319667) investigating isatuximab (Sarclisa) plus bortezomib, lenalidomide (Revlimid), and dexamethasone (Isa-VRd) in patients with newly diagnosed multiple myeloma.

Related Videos
4 experts are featured in this series.
Michael R. Bishop, MD
Lori A Leslie, MD
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Related Content
OncLive’s December Roundup of Key FDA Approvals in Oncology
December 30th 2024

OncLive’s December Roundup of Key FDA Approvals in Oncology

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Rafael Fonseca, MD
December 30th 2024

Working on the Frontlines of a Revolution in Multiple Myeloma Care

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Colorectal Cancer | stock.adobe.com
December 23rd 2024

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

Lung cancer, Image credit: Axel Kock – stock.adobe.com
December 23rd 2024

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC